NASDAQ · IBIO
iBio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IBIO: Nov 11, 2026
iBio, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.06. The reported EPS for the same quarter last year was $-0.11.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.06 | $-0.05 | $-0.08 | 4 |
| Dec 2026 | $-0.08 | $-0.06 | $-0.10 | 4 |
| Mar 2027 | $-0.08 | $-0.06 | $-0.10 | 4 |
| Jun 2027 | $-0.08 | $-0.05 | $-0.10 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks · BNK Invest- RTTNews · Oct 13, 7:51 AM EDTIBio Reprots Preclinical Data Showing Potential For Muscle Preservation With IBIO-610(RTTNews) – iBio, Inc. (IBIO) presented new preclinical data showing that its obesity therapy, IBIO-610, may help preserve muscle when used alongside GLP-1 based weight-loss treatment.
- Fintel · Sep 17, 2:23 PM EDTHC Wainwright & Co. initiates coverage of iBio with a Buy ratingFintel reports that on September 17, 2026, HC Wainwright & Co. initiated coverage of iBio (NASDAQCM:IBIO) with a Buy recommendation. iBio, Inc., headquartered in the United States, operates within the biotechnology industry, focusing primarily on developing plant-based biopha
- RTTNews · Aug 4, 8:01 AM EDTIBio Names Molly Carr As Chief Medical Officer(RTTNews) – iBio, Inc. (IBIO), a clinical-stage biotechnology company, on Tuesday announced the appointment of Molly Carr as its chief medical officer.
- RTTNews · Jul 2, 10:09 AM EDTWeekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal(RTTNews) – The holiday-shortened week delivered no shortage of action for the biotech sector, with a mix of FDA, China, Canada, and EU approvals, acquisitions, and positive clinical readouts, alongside regulatory rejections, program discontinuations, and trial goal misses.
- RTTNews · Jul 1, 8:38 AM EDTIBio's IBIO-610 Achieves Near-Complete Activin E Inhibition In Obese Primate Study(RTTNews) – iBio, Inc. (IBIO) announced new preclinical results showing that a single dose of its antibody candidate IBIO-610 reduced active Activin E levels by up to 98% in obese non-human primates, with suppression lasting through eight weeks.
- Fintel · Mar 27, 8:50 PM EDTiBio (IBIO) Price Target Increased by 18.73% to 5.47The average one-year price target for iBio (NasdaqCM:IBIO) has been revised to $5.47 / share. This is an increase of 18.73% from the prior estimate of $4.61 dated February 21, 2026. The price target is an average of many targets provided by analysts. The lates
- Fintel · Mar 3, 7:03 PM ESTJones Trading Initiates Coverage of iBio (IBIO) with Buy RecommendationFintel reports that on March 3, 2026, Jones Trading initiated coverage of iBio (NasdaqCM:IBIO) with a Buy recommendation. Analyst Price Forecast Suggests 71.39% Upside
- Zacks · Feb 3, 10:00 AM ESTCRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Feb 2, 10:00 AM ESTiBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseiBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- BNK Invest · Jan 15, 12:34 PM ESTThursday Sector Laggards: Drugs, Biotechnology StocksIn trading on Thursday, drugs shares were relative laggards, down on the day by about 1.3%. Helping drag down the group were shares of Regencell Bioscience Holdings, down about 11.9% and shares of iBio down about 9.4% on the day. Also lagging the market Thursday are biotechnol
- RTTNews · Dec 9, 12:04 AM ESTAfter-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance(RTTNews) – Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance.
- Fintel · Dec 6, 8:23 AM ESTiBio (IBIO) Price Target Increased by 14.56% to 4.81The average one-year price target for iBio (NasdaqCM:IBIO) has been revised to $4.81 / share. This is an increase of 14.56% from the prior estimate of $4.20 dated November 14, 2025. The price target is an average of many targets provided by analysts. The lates
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for iBio, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.